Discontinuation of Zoladex® 3.6mg Implant

HPS Pharmacies wish to give notice that AstraZeneca is discontinuing Zoladex^® 3.6mg Implant as follows:

Zoladex^® Implant 
Goserelin 3.6mg
ARTG 24368

Zoladex^® 3.6mg Implant is set to be discontinued on 1^st November 2026. Patients should consult their healthcare professional to discuss alternative treatment options.

The Zoladex^® 10.8mg implant will remain available. This presentation is currently only registered and reimbursed in Australia for eligible prostate cancer patients. AstraZeneca is preparing an application to have the approved indications expanded to include breast cancer patients who are hormone receptor positive.

Retain this notice in a prominent position, including in other related business units for one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.

Should you require further information regarding this matter, please contact AstraZeneca on 1800 805 342 or your pharmacist at HPS Pharmacies.

Download PDF